PDF factsheet
      Z

Selective estrogen receptor downregulators (SERDs) in advanced breast cancer (metastatic) for first line endocrine therapy, clinical trials results

fulvestrant + anastrozole versus anastrozole
FACT (Bergh), 2012
NCT00256698
fulvestrant 500 mg intramuscular on day 1 and 250mgon days 15 and 29 and thereafter every fourth week3 days, until proven progression or undue toxicity, in combination with anastrozole 1 mg orally per day
versus
anastrozole orally at 1 mg per day until proven progression or undue toxicity
first-line therapy for patients with receptor-positive postmenopausal breast cancer opan-label
canada
Mehta(SWOG-S0226), 2012
NCT00075764
Fulvestrant was administered intramuscularly at a dose of 500 mg on day 1 and 250 mg on days 14 and 28 and monthly thereafter.
versus
1 mg of anastrozole orally every day (group 1), with crossover to fulvestrant alone strongly encouraged if the disease progressed,
Postmenopausal women with previously untreated with hormone-receptor (HR)-positive
fulvestrant 250mg versus tamoxifen
9238IL/0025, 0
NCT00241449
intramuscular injection 250 mg
versus
first-line treatment for postmenopausal women with advanced breast cancer.double-blind
USA
0025 (Howell), 2004
fulvestrant 250 mg, via intramuscular injection, once monthly;
versus
tamoxifen 20 mg, orally, once daily
advanced breast cancer in postmenopausal women previously untreated with endocrine therapydouble-blind
fulvestrant 500mg versus anastrozole
FIRST (Robertson), 2010
NCT00274469
500 mg intramuscular injection
versus
anastrozole 1 mg oral tablet
First Line Hormonal Treatment for Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer

  Options


in first

in second

  Filter